{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:23:47Z","timestamp":1773408227357,"version":"3.50.1"},"reference-count":98,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Although the Coronavirus disease 2019 (COVID-19) pandemic has ended, there are still many important lessons we can learn, as the pandemic profoundly affected every area of laboratory practice. During the pandemic, extensive changes to laboratory staffing had to be implemented, as many healthcare institutions required regular screening of all healthcare staff. Several studies examined the effectiveness of different screening regimens and concluded that repeated testing, even with lower sensitivity tests, could rival the performance of gold-standard RT-PCR testing in the detection of new cases. Many assay evaluations were performed both in the earlier and later periods of the pandemic. They included both nucleocapsid\/spike antibodies and automated antigen assays. Early in the pandemic, it was generally agreed that the initial nucleocapsid antibody assays had poor sensitivity when used before 14 days of disease onset, with total or IgG antibodies being preferred over the use of IgM. Spike antibody assays gradually replaced nucleocapsid antibody assays, as most people were vaccinated. Spike antibodies tracked the rise in antibodies after vaccination with mRNA vaccines and became invaluable in the assessment of vaccine response. Studies demonstrated robust antibody secretion with each vaccine dose and could last for several months post-vaccination. When antigen testing was introduced, they became effective tools to identify affected patients when used serially or in an orthogonal fashion with RT-PCR testing. Despite the numerous findings during the pandemic period, research in COVID-19 has slowed. To this day it is difficult to identify a true neutralizing antibody test for the virus. An appropriate antibody level that would confer protective immunity against the plethora of new variants remains elusive. We hope that a summary of events during the pandemic could provide important insights to consider in planning for the next viral pandemic.<\/jats:p>","DOI":"10.3390\/vaccines13010009","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T21:13:18Z","timestamp":1735247598000},"page":"9","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing"],"prefix":"10.3390","volume":"13","author":[{"given":"Chin Shern","family":"Lau","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen M. L.","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-8836","authenticated-orcid":false,"given":"Tar Choon","family":"Aw","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore"},{"name":"Department of Medicine, National University of Singapore, Singapore 117599, Singapore"},{"name":"Academic Pathology Program, Duke-NUS Graduate Medical School, Singapore 169857, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_2","unstructured":"World Health Organization (2024, December 18). Statement on the Fifteenth Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Coronavirus Disease (COVID-19) Pandemic, 5 May 2023. Available online: https:\/\/www.who.int\/europe\/news-room\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic."},{"key":"ref_3","unstructured":"European Centre for Disease Prevention and Control (2024, December 18). SARS-CoV-2 Variants of Concern as of 29 November 2024, Available online: https:\/\/www.ecdc.europa.eu\/en\/covid-19\/variants-concern."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gitman, M.R., Shaban, M.V., Paniz-Mondolfi, A.E., and Sordillo, E.M. (2021). Laboratory Diagnosis of SARS-CoV-2 Pneumonia. Diagnostics, 11.","DOI":"10.3390\/diagnostics11071270"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/2010105820952486","article-title":"Laboratory practice in the face of Covid-19","volume":"30","author":"Lau","year":"2021","journal-title":"Proc. Singap. Healthc."},{"key":"ref_6","unstructured":"World Health Organization (2024, November 27). Laboratory Testing for Coronavirus Disease (COVID-19) in Suspected Human Cases: Interim Guidance, 19 March 2020. Available online: https:\/\/iris.who.int\/handle\/10665\/331501."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"Killingley","year":"2022","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lau, C.S., and Aw, T.C. (2022). SARS-CoV-2 Antigen Testing Intervals: Twice or Thrice a Week?. Diagnostics, 12.","DOI":"10.3390\/diagnostics12051039"},{"key":"ref_9","first-page":"CD013652","article-title":"Antibody tests for identification of current and past infection with SARS-CoV-2","volume":"6","author":"Deeks","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/jalm\/jfaa134","article-title":"Evaluation of an electrochemiluminescent SARS-CoV-2 antibody assay","volume":"5","author":"Lau","year":"2020","journal-title":"J. Appl. Lab. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cca.2020.09.005","article-title":"Performance of an automated chemiluminescence SARS-CoV-2 Ig-G assay","volume":"510","author":"Lau","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00201","DOI":"10.1016\/j.plabm.2021.e00201","article-title":"Performance of two rapid point of care SARS-COV-2 antibody assays against laboratory-based automated chemiluminescent immunoassays for SARS-COV-2 IG-G, IG-M and total antibodies","volume":"24","author":"Lau","year":"2021","journal-title":"Pract. Lab. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/clinchem\/hvaa131","article-title":"Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies","volume":"66","author":"Favresse","year":"2020","journal-title":"Clin. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2000180","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000180","article-title":"Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020","volume":"25","author":"Mizumoto","year":"2020","journal-title":"Euro Surveill."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00941-20","DOI":"10.1128\/JCM.00941-20","article-title":"Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho","volume":"58","author":"Bryan","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_18","unstructured":"National SARS-CoV-2 Serology Assay Evaluation Group (2020). Performance characteristics of five immunoassays for SARS-CoV-2: A head-to-head benchmark comparison. Lancet Infect. Dis., 20, 1390\u20131400."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-020-0659-0","article-title":"Evaluation of SARS-CoV-2 serology assays reveals a range of test performance","volume":"38","author":"Whitman","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"m2516","DOI":"10.1136\/bmj.m2516","article-title":"Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis","volume":"370","author":"Bastos","year":"2020","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e00230","DOI":"10.1016\/j.plabm.2021.e00230","article-title":"Performance of an automated chemiluminescent immunoassay for SARS-COV-2 IgM and head-to-head comparison of Abbott and Roche COVID-19 antibody assays","volume":"25","author":"Lau","year":"2021","journal-title":"Pract. Lab. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s41591-020-0949-6","article-title":"Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China","volume":"26","author":"Xu","year":"2020","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Huang","year":"2020","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"114224","DOI":"10.1016\/j.jviromet.2021.114224","article-title":"Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms","volume":"296","author":"Lau","year":"2021","journal-title":"J. Virol. Methods"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbrc.2020.04.136","article-title":"Biochemical characterization of SARS-CoV-2 nucleocapsid protein","volume":"527","author":"Zeng","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41551-020-00660-2","article-title":"Neutralizing antibodies for the treatment of COVID-19","volume":"4","author":"Jiang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 Vaccines: Status Report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e00257","DOI":"10.1016\/j.plabm.2021.e00257","article-title":"Performance of the Roche\/Snibe electrochemiluminescent anti-SARS-COV-2 spike assays compared to the Roche\/Abbott IgG nucleocapsid and Abbott IgM spike assays","volume":"27","author":"Lau","year":"2021","journal-title":"Pract. Lab. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/s41467-020-19943-y","article-title":"Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19","volume":"11","author":"Kening","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1093\/cid\/ciab004","article-title":"The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers","volume":"73","author":"Lumley","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1007\/s00125-020-05284-4","article-title":"Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: An observational cohort study","volume":"63","author":"Lampasona","year":"2020","journal-title":"Diabetologia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiaa273","article-title":"Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients with Coronavirus Disease 2019","volume":"222","author":"Burbelo","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00461-20","DOI":"10.1128\/JCM.00461-20","article-title":"Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2","volume":"58","author":"Liu","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1557.e1","DOI":"10.1016\/j.cmi.2020.07.038","article-title":"Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs","volume":"26","author":"Elslande","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Perkmann, T., Perkmann-Nagele, N., Koller, T., Mucher, P., Radakovics, A., Marculescu, R., Wolzt, M., Wagner, O.F., Binder, C., and Haslacher, H. (2021). Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: A Head-to-Head Comparison of Five Quantitative Assays. Microbiol. Spectr., 9.","DOI":"10.1128\/Spectrum.00247-21"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1126\/science.abf9648","article-title":"The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia","volume":"372","author":"Pavelka","year":"2021","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lau, C.S., and Aw, T.C. (2021). Disease Prevalence Matters: Challenge for SARS-CoV-2 Testing. Antibodies, 10.","DOI":"10.3390\/antib10040050"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.7861\/clinmed.2020-0839","article-title":"The impact of false positive COVID-19 results in an area of low prevalence","volume":"21","author":"Healy","year":"2021","journal-title":"Clin. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat. Med."},{"key":"ref_41","first-page":"147","article-title":"SARS-CoV-2 viral load and shedding kinetics","volume":"21","author":"Puhach","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1056\/NEJMp2025631","article-title":"Rethinking Covid-19 Test Sensitivity\u2014A Strategy for Containment","volume":"383","author":"Mina","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.abe9187","article-title":"COVID-19 testing: One size does not fit all","volume":"371","author":"Mina","year":"2021","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e2861","DOI":"10.1093\/cid\/ciaa1706","article-title":"Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates with Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture","volume":"73","author":"Pekosz","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eabd5393","DOI":"10.1126\/sciadv.abd5393","article-title":"Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening","volume":"7","author":"Larremore","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_46","unstructured":"Centers for Disease Control and Prevention (2024, November 28). Guidance for Antigen Testing for SARS-CoV-2 for Healthcare Providers Testing Individuals in the Community, 4 March 2022, Available online: https:\/\/stacks.cdc.gov\/view\/cdc\/115045."},{"key":"ref_47","first-page":"CD013705","article-title":"Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection","volume":"8","author":"Dinnes","year":"2020","journal-title":"Chochrane Database Syst. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijid.2021.07.043","article-title":"Performance of a SARS-CoV-2 antigen rapid immunoassay in patients admitted to the emergency department","volume":"110","author":"Leli","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"104654","DOI":"10.1016\/j.jcv.2020.104654","article-title":"Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2","volume":"132","author":"Cerutti","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/infdis\/jiab337","article-title":"Longitudinal Assessment of Diagnostic Test Performance over the Course of Acute SARS-CoV-2 Infection","volume":"224","author":"Smith","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamainternmed.2022.1827","article-title":"Comparison of Home Antigen Testing with RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection","volume":"182","author":"Chu","year":"2022","journal-title":"JAMA Intern Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lau, C.S., Phua, S.K., Hoo, S.P., Jiang, B., and Aw, T.C. (2022). Evaluation and Validation of the Roche Elecsys SARS-CoV-2 Antigen Electro-Chemiluminescent Immunoassay in a Southeast Asian Region. Vaccines, 10.","DOI":"10.3390\/vaccines10020198"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Saito, K., Ai, T., Kawai, A., Matsui, J., Fukushima, Y., Kikukawa, N., Kyoutou, T., Chonan, M., Kawakami, T., and Hosaka, Y. (2021). Performance and usefulness of a novel automated immunoassay HISCL SARS-CoV-2 Antigen assay kit for the diagnosis of COVID-19. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-02636-x"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Mitchell, S.L., Orris, S., Freeman, T., Freeman, M.C., Adam, M., Axe, M., Gribschaw, J., Suyama, J., Hoberman, A., and Wells, A. (2021). Performance of SARS-CoV-2 antigen testing in symptomatic and asymptomatic adults: A single-center evaluation. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06716-1"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00430-021-00719-0","article-title":"Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern","volume":"210","author":"Osterman","year":"2021","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"105048","DOI":"10.1016\/j.jcv.2021.105048","article-title":"Performance of a high-throughput, automated enzyme immunoassay for the detection of SARS-CoV-2 antigen, including in viral \u201cvariants of concern\u201d: Implications for clinical use","volume":"146","author":"Fourati","year":"2022","journal-title":"J. Clin. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMc2102051","article-title":"Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine","volume":"384","author":"Bradley","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cca.2021.03.007","article-title":"Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer","volume":"518","author":"Mueller","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"ref_59","first-page":"117","article-title":"BNT162b2 mRNA COVID-19 Vaccine Elicited Antibody Responses in COVID-19-na\u00efve Subjects","volume":"2","author":"Lau","year":"2021","journal-title":"J. Exp. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Lau, C.S., Phua, S.K., Liang, Y.L., Oh, H.M.L., and Aw, T.C. (2021). Robust SARS-CoV-2 Antibody Responses in Asian COVID-Na\u00efve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine. Vaccines, 9.","DOI":"10.3390\/vaccines9111241"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15585\/mmwr.mm7044e2","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines\u2014United States, 2021","volume":"70","author":"Mbaeyi","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Gro\u00df, R., Zanoni, M., Seidel, A., Conzelmann, C., Gilg, A., Krnavek, D., Erdemci-Evin, S., Mayer, B., Hoffmann, M., and Pohlmann, S. (2022). Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. eBioMedicine, 75.","DOI":"10.1016\/j.ebiom.2021.103761"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lau, C.S., Phua, S.K., Liang, Y.L., Oh, M.L.H., and Aw, T.C. (2022). SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore. Vaccines, 10.","DOI":"10.3390\/vaccines10020331"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lau, C.S., Oh, M.L.H., Phua, S.K., Liang, Y.L., and Aw, T.C. (2022). 210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine. Vaccines, 10.","DOI":"10.3390\/vaccines10101703"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s43856-024-00457-3","article-title":"Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection","volume":"4","author":"Reinholm","year":"2024","journal-title":"Commun. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Lee, Y.J., Choi, J.Y., Yang, J., Baek, J.Y., Kim, H.J., Kim, S.H., Jeong, H., Kim, M.S., Lee, H.W., and Kang, G. (2023). Longitudinal kinetics of neutralizing antibodies against circulating SARS-CoV-2 variants and estimated level of group immunity of booster-vaccinated individuals during omicron-dominated COVID-19 outbreaks in the Republic of Korea, 2022. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.01655-23"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron","volume":"386","author":"Gonen","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19","volume":"384","author":"Suthar","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/22221751.2021.1953403","article-title":"Antibody titres decline 3-month post-vaccination with BNT162b2","volume":"10","author":"Favresse","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bayart, J.L., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S.V., Roy, T., and Gerin, V. (2021). Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. Vaccines, 9.","DOI":"10.21203\/rs.3.rs-862966\/v1"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.2021.19885","article-title":"Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged \u226560 Years","volume":"326","author":"Stemmer","year":"2021","journal-title":"JAMA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.jfma.2022.08.017","article-title":"Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021","volume":"121","author":"Lin","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Lee, N., Jeong, S., Lee, S.K., Cho, E.J., Hyun, J., Park, M.J., Song, W., and Kim, H.S. (2022). Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination. Vaccines, 10.","DOI":"10.3390\/vaccines10071143"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2096970","DOI":"10.1080\/21645515.2022.2096970","article-title":"CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2","volume":"18","author":"Jin","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijid.2022.03.028","article-title":"Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study","volume":"119","author":"Suah","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/cid\/ciac288","article-title":"Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore","volume":"75","author":"Premikha","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Lau, C.S., Oh, M.L.H., Phua, S.K., Liang, Y.L., Li, Y., Huo, J., Huang, Y., Zhang, B., Xu, S., and Aw, T.C. (2022). Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore. Antibodies, 11.","DOI":"10.3390\/antib11020038"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Lau, C.S., Thundyil, J., Oh, M.L.H., Phua, S.K., Liang, Y.L., Li, Y., Huo, J., Huang, Y., Zhang, B., and Xu, S. (2022). Neutralizing and Total\/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination up to 90 Days Post-Booster. Antibodies, 11.","DOI":"10.3390\/antib11040070"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S2666-5247(21)00177-4","article-title":"Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19","volume":"2","author":"Lim","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2666-5247(21)00305-0","article-title":"Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: A prospective, longitudinal population-based study","volume":"3","author":"Barin","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Khong, K.W., Liu, D., Leung, K.Y., Lu, L., Lam, H.Y., Chen, L., Chan, P.C., Lam, H.M., Xie, X., and Zhang, R. (2022). Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant. Vaccines, 10.","DOI":"10.3390\/vaccines10020160"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: A mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/clinchem\/hvaa262","article-title":"Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2","volume":"67","author":"Suhandynata","year":"2021","journal-title":"Clin. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study","volume":"373","author":"Bernal","year":"2021","journal-title":"BMJ"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers\u2014Eight U.S. Locations, December 2020\u2013March 2021","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2027160","DOI":"10.1080\/21645515.2022.2027160","article-title":"The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: A systematic review","volume":"18","author":"Mohammed","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"105345","DOI":"10.1016\/j.jcv.2022.105345","article-title":"Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology","volume":"158","author":"Perkmann","year":"2023","journal-title":"J. Clin. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2666-5247(23)00216-1","article-title":"Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): An open-label, randomised trial","volume":"4","author":"Leung","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/clinchem\/hvad169","article-title":"Clinical Assessment of SARS-CoV-2 Antibodies in Oral Fluids Following Infection and Vaccination","volume":"70","author":"Heaney","year":"2024","journal-title":"Clin. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/10408363.2023.2254390","article-title":"Applications of SARS-CoV-2 serological testing: Impact of test performance, sample matrices, and patient characteristics","volume":"61","author":"Fung","year":"2024","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2666-5247(23)00258-6","article-title":"The importance of using WHO International Standards to harmonise SARS-CoV-2 serological assays","volume":"5","author":"Hempel","year":"2024","journal-title":"Lancet Microbe"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/1\/9\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:00:48Z","timestamp":1760115648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/1\/9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["vaccines13010009"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13010009","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}